The Cardiac Biomarker Testing Market was valued at USD 4.53 billion in 2023 and is projected to reach USD 10.21 billion by 2032, registering a CAGR of 9.47% over the forecast period from 2024 to 2032. The growing burden of cardiovascular diseases (CVDs), the increasing adoption of point-of-care (POC) testing, and technological advancements in biomarker...